◀ Back to MAPK6
MAP2K5 — MAPK6
Pathways - manually collected, often from reviews:
-
WikiPathways ESC Pluripotency Pathways:
MAP2K1/MAP2K3/SEPP1/MAP2K5/MAP2K6/MAP2K2
→
MAPK7/MAPK1/MAPK6/MAPK4/MAPK12
(activation)
-
WikiPathways Focal Adhesion:
SEPP1/MAP2K5/MAP2K6/MAP2K2/MAP2K3/MAP2K1
→
MAPK4/MAPK7/MAPK12/MAPK1/MAPK6
(activation)
Text-mined interactions from Literome
Martel-Pelletier et al., Arthritis Rheum 1999
(Osteoarthritis) :
Within minutes, IL-17 induced the phosphorylation of
mitogen activated protein kinase kinase-1/2 ( MEK-1/2 ), -3/6 ( MKK-3/6 ), p44/42, p38, and inhibitor of nuclear factor kappaB ( I kappaB)-alpha, as well as the
activation of
mitogen activated protein kinase activated protein kinase-1 and -2 ( MAPKAPK-1 and -2 )
Tu et al., J Biomed Sci 2001
(Carcinoma, Hepatocellular) :
On the other hand, PD98059, a specific inhibitor of
mitogen activated protein kinase kinase ,
blocks TPA induced
MAPK activation but has no effect on TPA induced tyrosine phosphorylation
Huang et al., Biochem Biophys Res Commun 2003
:
MAP3Ks are components of a three tiered protein kinase pathway in which a MAP3K phosphorylates and activates a
mitogen activated protein kinase kinase ( MAP2K ), which in turn
activates a
mitogen activated protein kinase ( MAPK )
Huwiler et al., Br J Pharmacol 1994
:
2. Both nucleotides stimulate phosphorylation and
activation of
mitogen activated protein kinase and a biphasic phosphorylation of the up-stream
mitogen activated protein kinase kinase
Daum et al., FEBS Lett 1998
:
Pervanadate inhibits
mitogen activated protein kinase kinase-1 in a
p38MAPK dependent manner